HCM
GSK icon

Hillman Capital Management’s GSK GSK Stock Holding History

Hillman Capital Management’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.38M Sell
97,432
-16,904
-15% -$916K 3.73% 4
2025
Q4 		$5.61M Sell
114,336
-27,443
-19% -$1.28M 3.53% 5
2025
Q3 		$6.12M Sell
141,779
-10,820
-7% -$423K 3.56% 6
2025
Q2 		$5.86M Sell
152,599
-12,544
-8% -$479K 3.2% 10
2025
Q1 		$6.4M Sell
165,143
-66,008
-29% -$2.42M 3.15% 8
2024
Q4 		$7.82M Buy
231,151
+34,255
+17% +$1.23M 2.9% 14
2024
Q3 		$8.05M Buy
196,896
+1,770
+0.9% +$72.4K 2.76% 16
2024
Q2 		$7.51M Sell
195,126
-38,360
-16% -$1.61M 2.65% 16
2024
Q1 		$10M Buy
233,486
+100
+0% +$4.12K 3.22% 6
2023
Q4 		$8.65M Buy
233,386
+522
+0.2% +$18.7K 2.99% 12
2023
Q3 		$8.44M Sell
232,864
-1,817
-0.8% -$64.5K 3.25% 5
2023
Q2 		$8.36M Sell
234,681
-2,735
-1% -$98.1K 2.95% 13
2023
Q1 		$8.45M Sell
237,416
-463
-0.2% -$16.2K 3.2% 8
2022
Q4 		$8.36M Sell
237,879
-6,099
-2% -$203K 3.28% 9
2022
Q3 		$7.18M Buy
243,978
+54,511
+29% +$2.07M 2.98% 11
2022
Q2 		$10.3M Buy
189,467
+916
+0.5% +$50.6K 3.75% 4
2022
Q1 		$10.3M Buy
188,551
+2,072
+1% +$113K 3.26% 2
2021
Q4 		$10.3M Sell
186,479
-6,942
-4% -$361K 3.53% 5
2021
Q3 		$9.24M Buy
193,421
+6,561
+4% +$330K 3.24% 12
2021
Q2 		$9.3M Buy
186,860
+1,208
+0.7% +$58K 3.54% 8
2021
Q1 		$8.28M Buy
185,652
+181,156
+4,029% +$8.22M 3.63% 6
2020
Q4 		$207K Buy
+4,496
New +$207K 0.11% 44

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Hillman Capital Management's GSK Position: Q1 2026 in Review

Hillman Capital Management reduced its GSK (GSK) stake by 15% in Q1 2026, selling an estimated $916K and leaving 97,432 shares worth $5.38M. The position accounts for 3.73% of the portfolio, ranked #4.

Hillman Capital Management first reported a position in GSK in Q4 2020 and has held it in 22 quarters since. The position peaked at $10.3M in Q2 2022. 1,034 funds tracked by Wall St. Rank hold GSK as of Q1 2026.

  • Hillman Capital Management held 97,432 shares of GSK worth $5.38M as of Q1 2026.
  • Hillman Capital Management sold 16,904 GSK shares in Q1 2026, an estimated $916K.
  • GSK made up 3.73% of Hillman Capital Management's portfolio in Q1 2026, its #4 holding.
  • Hillman Capital Management first reported a position in GSK in Q4 2020 and has held it in 22 quarters since.
  • Hillman Capital Management's GSK position peaked at $10.3M in Q2 2022.
  • 1,034 funds tracked by Wall St. Rank held GSK as of Q1 2026.

Based on Hillman Capital Management's 13F filing for Q1 2026, filed 15 May 2026.